Walleye Trading
PRTK

Walleye Trading’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Walleye Trading’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-500
Closed -$5K – 5496
2018
Q3 		$5K Buy
+500
New +$5.04K ﹤0.01% 5123

Other funds holding PRTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Walleye Trading's PRTK Position: Q3 2021 in Review

Walleye Trading sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2021, closing a stake of 13,573 shares — an estimated $93K sold.

Walleye Trading first reported a position in PRTK in Q3 2018 and held it in 4 quarters. The position peaked at $151K in Q2 2019. 105 funds tracked by Wall St. Rank hold PRTK as of Q3 2021.

  • Walleye Trading reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
  • Walleye Trading sold 13,573 Paratek Pharmaceuticals, Inc. shares in Q3 2021, an estimated $93K.
  • Walleye Trading first reported a position in Paratek Pharmaceuticals, Inc. in Q3 2018 and held it in 4 quarters.
  • Walleye Trading's Paratek Pharmaceuticals, Inc. position peaked at $151K in Q2 2019.
  • 105 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2021.

Based on Walleye Trading's 13F filing for Q3 2021, filed 15 Nov 2021.